Q-omics provides the consensus-scored XACT profile across patient tissues and cancer cell-line models. XACT expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, XACT is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, XACT RNA expression shows 8,627 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where XACT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XACT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XACT survival associations across molecular data types. XACT RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XACT RNA expression–survival associations across cancer types. High XACT expression shows unfavorable associations in KIRC, MESO, COAD, LUAD and KIRP, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for XACT RNA expression.
This table summarizes XACT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for XACT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XACT shows higher tumor expression in LUSC. The LUSC box plot shows higher XACT RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .044).
This table shows molecular features associated with XACT in patient tissues and cancer cell lines. In patient samples, XACT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
